| Serous Neoplasm studied in …STUDIED_INderived10 of 224show all (up to 200) |
|---|
| → studied in | NCT02345265Phase 2 · active not recruiting Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 224 trials mapped (103 active) | — | — | Fallopian Tube Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 224 trials mapped (103 active) | — | — | Ovarian Serous Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 224 trials mapped (103 active) | — | — | Fallopian Tube Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 224 trials mapped (103 active) | — | — | Endometrial Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · condition mapped CURATED_BROADER · 224 trials mapped (103 active) | — | — | Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05956093NA · active not recruiting 68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study · condition mapped ONTOLOGY_EXACT · 224 trials mapped (103 active) | — | — | High-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03564340Phase 1/Phase 2 · recruiting Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers · condition mapped ONTOLOGY_EXACT · 224 trials mapped (103 active) | — | — | Low-Grade Serous Ovarian Cancer | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05276973Phase 1 · active not recruiting Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 224 trials mapped (103 active) | — | — | Fallopian Tube High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped CURATED_BROADER · 224 trials mapped (103 active) | — | — | Fallopian Tube High Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07832227Phase 2 · not yet recruiting Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial · condition mapped ALIAS · 224 trials mapped (103 active) | — | — | Ovarian Low Grade Serous Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |